Thus, whether anti-PD-1/PD-L1 based combination treatments could show better efficacy than anti-PD-1/PD-L1 monotherapy in NSCLC patients with less-selected BrMs remains unknown. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.